These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37498791)

  • 41. Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: First results in a tertiary hospital in Madrid.
    Molina Gutiérrez MÁ; de Miguel Lavisier B; Ruiz Domínguez JA; García de Oteyza M; Velasco Molina VM; Gutiérrez Arroyo A; de Ceano-Vivas M
    Enferm Infecc Microbiol Clin (Engl Ed); 2024; 42(7):367-372. PubMed ID: 39013707
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Palivizumab in the prevention of respiratory syncytial virus disease.
    Krilov LR
    Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation.
    Chan PW; Abdel-Latif ME
    Acta Paediatr; 2003 Apr; 92(4):481-5. PubMed ID: 12801117
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Passive immunization for the prevention of otitis media.
    Englund JA; Glezen WP
    Vaccine; 2000 Dec; 19 Suppl 1():S116-21. PubMed ID: 11163474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunization against viral respiratory disease: a review.
    Greenberg HB; Piedra PA
    Pediatr Infect Dis J; 2004 Nov; 23(11 Suppl):S254-61. PubMed ID: 15577581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RSV disease in infants and young children: Can we see a brighter future?
    Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
    Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants.
    Principi N; Autore G; Perrone S; Esposito S
    Expert Opin Pharmacother; 2023 Apr; 24(6):747-762. PubMed ID: 37013721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccination against RSV: is maternal vaccination a good alternative to other approaches?
    Kaaijk P; Luytjes W; Rots NY
    Hum Vaccin Immunother; 2013 Jun; 9(6):1263-7. PubMed ID: 23442726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment and prevention of respiratory syncytial virus infection.
    Kneyber MC; Moll HA; de Groot R
    Eur J Pediatr; 2000 Jun; 159(6):399-411. PubMed ID: 10867843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Strategies for preventing respiratory syncytial virus.
    Forbes M
    Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New strategies for the prevention of respiratory syncytial virus (RSV).
    Messina A; Germano C; Avellis V; Tavella E; Dodaro V; Massaro A; Vitale R; Masturzo B; Manzoni P
    Early Hum Dev; 2022 Nov; 174():105666. PubMed ID: 36174288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory syncytial virus: A new era.
    Ruiz-Galiana J; Cantón R; De Lucas Ramos P; García-Botella A; García-Lledó A; Hernández-Sampelayo T; Gómez-Pavón J; González Del Castillo J; Martín-Delgado MC; Martín Sánchez FJ; Martínez-Sellés M; Molero García JM; Moreno Guillén S; Rodríguez-Artalejo FJ; Rodríguez Fernandez R; Kestler M; Bouza E
    Rev Esp Quimioter; 2024 Apr; 37(2):134-148. PubMed ID: 38205560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.